May 14, 2014 / 6:19 AM / 3 years ago

AstraZeneca and Incyte to study cancer drugs together

LONDON, May 14 (Reuters) - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte , highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.

The agreement will test a combination of two different drugs designed to boost the immune system to help it fight tumours - AstraZeneca's MEDI4736 and Incyte's INCB24360 - in a Phase I/II clinical study, the British firm said on Wednesday.

Reporting by Ben Hirschler; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below